These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28961812)

  • 1. Maximally effective dosing regimens of meropenem in patients with septic shock.
    Sjövall F; Alobaid AS; Wallis SC; Perner A; Lipman J; Roberts JA
    J Antimicrob Chemother; 2018 Jan; 73(1):191-198. PubMed ID: 28961812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining optimal dosing of ciprofloxacin in patients with septic shock.
    Roberts JA; Alobaid AS; Wallis SC; Perner A; Lipman J; Sjövall F
    J Antimicrob Chemother; 2019 Jun; 74(6):1662-1669. PubMed ID: 30809648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.
    Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2016 Nov; 48(5):542-546. PubMed ID: 27771187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
    Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study.
    Eisert A; Lanckohr C; Frey J; Frey O; Wicha SG; Horn D; Ellger B; Schuerholz T; Marx G; Simon TP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106289. PubMed ID: 33515688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
    Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.
    Usman M; Frey OR; Hempel G
    Eur J Clin Pharmacol; 2017 Mar; 73(3):333-342. PubMed ID: 27966034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.
    Kees MG; Minichmayr IK; Moritz S; Beck S; Wicha SG; Kees F; Kloft C; Steinke T
    J Clin Pharmacol; 2016 Mar; 56(3):307-15. PubMed ID: 26222202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
    Cies JJ; Moore WS; Dickerman MJ; Small C; Carella D; Chopra A; Parker J
    Pharmacotherapy; 2014 Oct; 34(10):e175-9. PubMed ID: 25146254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock.
    Taccone FS; Cotton F; Roisin S; Vincent JL; Jacobs F
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2129-31. PubMed ID: 22290984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
    Roger C; Wallis SC; Louart B; Lefrant JY; Lipman J; Muller L; Roberts JA
    J Antimicrob Chemother; 2016 Jun; 71(6):1643-50. PubMed ID: 26957490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
    Eguchi K; Kanazawa K; Shimizudani T; Kanemitsu K; Kaku M
    J Infect Chemother; 2010 Feb; 16(1):1-9. PubMed ID: 20072800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.